Arrowhead (ARWR) announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA interference therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia. Zodasiran is the fourth investigational RNAi-based candidate developed by Arrowhead to reach late-stage pivotal studies, after investigational drugs plozasiran, fazirsiran and olpasiran.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead completes enrollment in SHASTA-3, SHASTA-4 and MUIR-3
- Arrowhead initiates Phase 1/2a study of ARO-ALK7
- Arrowhead Pharmaceuticals: Strong Buy Rating Backed by Promising RNAi Pipeline and Strategic Partnerships
- Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Biotech Alert: Searches spiking for these stocks today